联邦制药附属公司创新药UBT251注射液获FDA批准开展II期临床试验
3月4日，联邦制药（03933）发布公告，近日公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局（FDA）批准，允许开展慢性肾脏病（CKD）适应症的II期临床试验。此前，该适应症已于2025年1月20日获得中国国家药品监督管理局的临床试验批准。
UBT251是一款长效GLP-1/GIP/GCG三靶点受体激动剂，公司的研发成果在临床前肥胖/糖尿病肾病药效模型中表现出明显优于司美格鲁肽的效果，尤其在改善肾脏尿白蛋白等相关肾损伤标志物和组织病理方面。
未来，该药物有望为代谢相关慢性肾病的治疗提供新选择，进一步满足临床用药需求。公司表示将持续致力于新产品研发，提升在生物医药行业的竞争力和创造力，为公司及其股东创造更大收益。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10